• Vaccine Name: Poliovirus vector expressing model antigen H2-Kb-restricted CTL epitope
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004705
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• H2-K1 gene engineering:
  • Type: Recombinant vector construction
  • Description: Recombinant poliovirus to induce CTL responses to a segment of the chicken ovalbumin gene, which encodes for the H2-Kb-restricted CTL epitope SIINFEKL, was cloned at the junction of the P1 and P2 regions (Mandl et al., 1998).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001052
  • Description: (Mandl et al., 1998)
• Preparation: A segment of the chicken ovalbumin gene, which includes the H2-Kb-restricted CTL epitope SIINFEKL, was cloned at the junction of the P1 and P2 regions (Mandl et al., 1998).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Transgenic mice expressing the PVR (26) were infected i.p. with 100 μl of 5 × 10^5 pfu of the recombinant viruses in PBS solution. The mice also received 2–3 booster shots of 1 × 10^6 of the same virus (Mandl et al., 1998).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were challenged by s.c. injection of 1 × 10^5 Ova expressing or parental B16F0 melanoma cells in 100 μl of PBS (Mandl et al., 1998).
• Efficacy: Inoculation of mice with recombinant poliovirus that expresses ovalbumin elicits an effective specific CTL response. Vaccination with the recombinant poliovirus expressing H2-Kb-restricted CTL epitope SIINFEKL of ovalbumin induced protective immunity against challenge with lethal doses of a malignant melanoma cell line expressing ovalbumin (Mandl et al., 1998).